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SUMMARY
A growing interest in rhinosinusitis in recent years resulted in two European 
Position Papers in Rhinosinusitis and Nasal Polyposis (EP3OS) documents, 
published in 2005 and 2007, respectively. The latter is intended to be a state-
of-the art review for specialists and general practitioners, updating the current 
knowledge on rhinosinusitis and nasal polyposis, proposing the guidance for 
deﬁ nitions and outcome measurements in research and providing an evidence-
based review of the available treatments. The present article brieﬂ y discusses 
the guidelines for acute rhinosinusitis (ARS) and chronic rhinosinusitis (CRS) 
diagnoses, as well as treatment recommendations provided by that document. 
Recent, epidemiological PROSINUS study of ARS, carried out in Spain, is also 
brieﬂ y reviewed, with special emphasis on Cyclamen europaeum extract use 
in ARS treatment. A new treatment approach is proposed, based on Cyclamen 
europaeum extract use in ARS and in the postoperative management of pa-
tients with CRS and nasal polyps undergoing endoscopic sinus surgery, which 
is associated with clinically conﬁ rmed, signiﬁ cant improvement of patients’ 
symptoms, nasal endoscopic signs and patient satisfaction in comparison to 
saline. These results are thought to be connected with nasal drainage-facilitat-
ing and paranasal sinuses-cleaning activities of the extract.
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Rhinosinusitis is a significant and increasing health 
problem which results in a large financial burden on 
society. The first European Position Paper in Rhino-
sinusitis and Nasal Polyposis (EP3OS) was published 
in 2005, simultaneously in the ENT and allergy litera-
ture. In the intervening couple of years an impressive 
number of high quality studies had been published 
looking at both the pathophysiology and treatment of 
the conditions and this resulted in the latest iteration 
of EP3OS in 2007 [1]. This EP3OS pocket guide offers 
evidence-based recommendations on its diagnosis and 
treatment while the EP3OS full document on which this 
is based is intended to be a state-of-the art review for 
the specialist as well as for the general practitioner: a) 
to update their knowledge of rhinosinusitis and nasal 
polyposis; b) to provide an evidence-based documented 
review of the diagnostic methods; c) to provide an 
evidence-based review of the available treatments; d) 
to propose a stepwise approach to the management of 
the disease; and e) to propose guidance for definitions 
and outcome measurements in research in different 
settings. The severity of disease may be assessed by 
total VAS score (0 to 10 cm): mild (0 a 3), moderate (>3 
a 7), and severe (>7 a 10) [1, 2].
Acute Rhinosinusitis (ARS)
Diagnosis is based on symptoms and imaging is not 
recommended except in case of severe disease, immu-
nocompetent patients, and signs of complications. ARS 
is defined as a sudden onset of at least two symptoms, 
one of them being nasal congestion/obstruction/block-
age or anterior/posterior nasal discharge, and facial 
pressure/pain or decrease/loss of smell [1, 3]. In com-
mon cold (mild ARS) symptoms last for less than 10 
days while in moderate and severe (fever, unilateral 
severe facial pain) ARS symptoms may increase after 
5 days or last for more than 10 days, but always for 
less than 12 weeks. Treatment of common cold is only 
symptomatic, while nasal corticosteroids in mono-
therapy (moderate) or with oral antibiotics (severe) are 
recommended in ARS [3, 4]. 
Chronic Rhinosinusitis (CRS) 
and nasal polyps
CRS, including nasal polyps, are defined as an in-
flammation of the nose and paranasal sinuses with at 
least two symptoms, one of them being nasal conges-
tion/obstruction/blockage or anterior/posterior nasal 
discharge, and facial pressure/pain or decrease/loss of 
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smell, lasting for more than 12 weeks [6]. In addition, 
diagnosis may be confirmed by nasal endoscopy (nasal 
polyps or mucupurulent discharge) and/or CT scan 
(mucosal abnormality in the sinuses or ostiomeatal 
complexes) [1, 3]. The treatment of CRS is based on the 
use of saline nasal lavages and long term nasal corti-
costeroids, either in spray (mild) or drops (moderate). In 
severe nasal polyps short courses of oral corticosteroids 
are also recommended. Endoscopic sinus surgery shall 
be performed only when medical treatment fails while 
optimal medical treatment should always be continued 
after surgery [3, 4, 5, 6].
The Prosinus study
An epidemiological study on ARS has been recently 
performed in Spain with the following conclusions are: 
1) ARS symptoms are predominantly of moderate to 
severe intensity with a significant impact on patient’s 
quality of life; 2) in the diagnosis, plain sinus x-ray 
are overused by both GPs and ENT specialists; 3) in 
the treatment, ENT specialists use less antibiotics and 
mucolytics than GPs; 4) the disease is cured in 83% 
of the cases within 4 weeks of treatment (mean: 13.7 
days); 5) Cyclamen european increases the cure rate 
of ARS when used both on top of other treatments or 
in monotherapy; and 5) the socioeconomic impact of 
ARS in the Spain is very high with a cost of 795 € per 
episode and 700 to 1,400 million € per year.
A new treatment approach
In the treatment of rhinosinusitis, a cleaning process is 
needed to improve the recovery of the nasal mucosa and 
to avoid postoperative complications. The lyophilized 
extract of Cyclamen europeum nasal spray is a new 
treatment that facilitates physiological drainage and 
cleaning of the paranasal sinuses through the mucous 
membranes. To date, three clinical trials have been 
conducted in Germany and the USA to evaluate the 
efficacy and safety of this product in monotherapy or 
adjunctive therapy  with antibiotics in patients diag-
nosed of moderate to severe ARS and in the postopera-
tive evolution of patients with CRS and nasal polyps 
undergoing endoscopic sinus surgery. The design was 
randomized, double-blind, placebo-controlled (ARS) 
or single-blind controlled with saline (CRS). Outcome 
measurements were: reported symptoms, mucopu-
rulent secretion (nasal endoscopy), sinus occupancy 
(CT scan), patient and investigator satisfaction, and 
safety evaluation (adverse events). In the ARS study 
(Germany), Cyclamen showed a statistical improvement 
in facial pain, endoscopic signs, and both patient and 
investigator satisfaction compared to placebo. Simi-
larly, in the USA trial, Cyclamen treatment resulted 
in a significant improvement in Total Symptom Score 
and sinus occlusion (CT scan), compared to baseline. 
In the CRS post-operative study (Germany), Cyclamen 
showed a statistical improvement of endoscopic signs 
compared to saline, and a similar improvement than 
saline in nasal symptoms and in both investigator and 
patient satisfaction. There were no safety concerns and 
unexpected adverse events with Cyclamen. In conclu-
sion, Cyclamen europeum is a new approach to the 
treatment of ARS and in the postoperative management 
of patients with CRS and nasal polyps undergoing 
endoscopic sinus surgery. 
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